Ruxolitinib inhibits cytokine production by human lung macrophages without impairing phagocytic ability

• 主要な著者: Nikola Mantov (著者), Mathilde Zrounba (著者), Marion Brollo (著者), S Grassin-Delyle (著者), Matthieu Glorion (著者), Mélanie David (著者), Emmanuel Naline (著者), Philippe Devillier (著者), Hélène Salvator (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Background: The Janus kinase (JAK) 1/2 inhibitor ruxolitinib has been approved in an indication of myelofibrosis and is a candidate for the treatment of a number of inflammatory or autoimmune diseases. We assessed the effects of ruxolitinib on lipopolysaccharide (LPS)- and poly (I:C)-induced cytokin...